Diseases & Conditions market research reports by DelveInsight

• Autoimmune Uveitis – Market Insight, Epidemiology, and Market Forecast – 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Autoimmune Uveitis – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight's ""Autoimmune Uveitis – Market Insights, Epidemiology, and Market Forecast – 2034"" report delivers an in-depth understanding of the Autoimmune Uveitis, historical and forecasted epidemiology as well as the A ... Read More

• Diabetic Neuropathic Pain- Pipeline Insight, 2024

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Diabetic Neuropathic Pain- Pipeline Insight, 2024 DelveInsight’s, “Diabetic Neuropathic Pain- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Diabetic Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including cli ... Read More

• Sickle Cell Disease - Epidemiology Forecast - 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 3,950

  Sickle Cell Disease - Epidemiology Forecast - 2034 Key Highlights In 2023, the United States accounted for the highest number of total prevalent cases of SCD trait with approximately 54% cases found in the 6MM. The prevalence of SCD cases was found to be high and rapidly increasing in the 6MM countr ... Read More

• Hemophilia B - Pipeline Insight, 2024

  May 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Hemophilia B - Pipeline Insight, 2024 DelveInsight’s, “Hemophilia B - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hemophilia Bpipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... Read More

• Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024 DelveInsight’s, “Primary Progressive Multiple Sclerosis- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Primary Progressive Multiple Sclerosis pipeline landscape. It covers t ... Read More

• Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2024 DelveInsight’s, “Relapsing-Remitting Multiple Sclerosis - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers ... Read More

• Acute Ocular Pain And Inflammation - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Acute Ocular Pain And Inflammation - Pipeline Insight, 2024 Acute Ocular Pain And Inflammation Overview ""Acute Ocular Pain And Inflammation Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute O ... Read More

• CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024 DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It cover ... Read More

• Malaria - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Malaria - Pipeline Insight, 2024 DelveInsight’s, Malaria - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers ... Read More

• Advanced Renal Cell Carcinoma- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,500

  Advanced Renal Cell Carcinoma- Pipeline Insight, 2024 DelveInsight’s, “Advanced Renal Cell Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, i ... Read More

• HER2 Negative Breast Cancer- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 3,000

  HER2 Negative Breast Cancer- Pipeline Insight, 2024 DelveInsight’s, “HER2 Negative Breast Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2 Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, includi ... Read More

• Celiac Disease- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Celiac Disease- Pipeline Insight, 2024 DelveInsight’s, “Celiac Disease- Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Celiac Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage prod ... Read More

• Unresectable Melanoma - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Unresectable Melanoma - Pipeline Insight, 2024 Unresectable Melanoma Overview ""Unresectable Melanoma Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Unresectable Melanoma market. A detailed pictu ... Read More

• Hemophilia A - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Hemophilia A - Pipeline Insight, 2024 DelveInsight’s, “Hemophilia A - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products ... Read More

• Genital Herpes - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Genital Herpes - Pipeline Insight, 2024 DelveInsight’s, “Genital Herpes - Pipeline Insight, 2024,” report provides comprehensive insights about 26+ companies and 28+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage p ... Read More

• Acute Lymphoblastic Leukemia (ALL) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Acute Lymphoblastic Leukemia (ALL) - Pipeline Insight, 2024 Acute Lymphoblastic Leukemia (ALL) Overview ""Acute Lymphoblastic Leukemia (ALL) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute L ... Read More

• Autoimmune Gastritis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Autoimmune Gastritis - Pipeline Insight, 2024 Autoimmune Gastritis Overview ""Autoimmune Gastritis Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Autoimmune Gastritis market. A detailed picture o ... Read More

• Autoimmune Hepatitis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Autoimmune Hepatitis - Pipeline Insight, 2024 DelveInsight’s, “Autoimmune Hepatitis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Autoimmune Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and no ... Read More

• Lyme Disease - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Lyme Disease - Pipeline Insight, 2024 DelveInsight’s, “Lyme Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lyme Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... Read More

• Non-Radiographic Axial Spondyloarthritis (nrAxSpA) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Non-Radiographic Axial Spondyloarthritis (nrAxSpA) - Pipeline Insight, 2024 Non-Radiographic Axial Spondyloarthritis (nrAxSpA) Overview ""Non-Radiographic Axial Spondyloarthritis (nrAxSpA) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development ... Read More

• Autoimmune pulmonary alveolar proteinosis (aPAP) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Autoimmune pulmonary alveolar proteinosis (aPAP) - Pipeline Insight, 2024 Autoimmune pulmonary alveolar proteinosis (aPAP) Overview ""Autoimmune pulmonary alveolar proteinosis (aPAP) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenar ... Read More

• Autoimmune Encephalitis (AE) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Autoimmune Encephalitis (AE) - Pipeline Insight, 2024 Autoimmune Encephalitis (AE) Overview ""Autoimmune Encephalitis (AE) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Autoimmune Encephalitis ( ... Read More

• Bladder Pain - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Bladder Pain - Pipeline Insight, 2024 Bladder Pain Overview ""Bladder Pain Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Bladder Pain market. A detailed picture of the Bladder Pain pipeline land ... Read More

• Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) - Pipeline Insight, 2024 Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Overview ""Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical developme ... Read More

• Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2024 DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline landscape. I ... Read More

< prev 9 10 11 12 13 14 15 16 17 18 next >